Лейкоцит как адекватная модель изучения характера изменений энергетического обмена в клетках сердца под влиянием кардиоцитопротекторов при ишемии миокарда

Целью данного исследования явилось определение возможности изучения характера влияния кардиоцитопротекторов на энергетический обмен в кардиомиоцитах на модели лейкоцитов периферической крови человека. Материалы и методы. Шестьдесят крыс линии Вистар были разделены на группы: 1) интактные крысы; 2) крысы с экспериментальной ишемией миокарда; 3) крысы с ишемией миокарда, которым вводили кардиоцитопротектор – триметазидин, 4) мельдоний, 5) цитофлавин и 6) этоксидол. Животных выводили из эксперимента через 10 суток после введения препаратов методом декапитации. Активность пируватдегидрогеназы и цитратсинтазы определяли в митохондриях гомогенатов миокарда и в митохондриях лейкоцитов спектрофотометрическими методами. Результаты. При моделировании ишемии миокарда выявлено снижение активности пируватдегидрогеназы и цитратсинтазы в кардиомиоцитах и в лейкоцитах. Введение кардиоцитопротекторов приводило к активации этих ферментов как в клетках сердца, так и в лейкоцитах крови. Получены прямые положительные корреляции между активностью пируватдегидрогеназы в митохондриях кардиомиоцитов и в митохондриях лейкоцитов (r = 0,811; p < 0,0001); между активностью цитратсинтазы в митохондриях кардиомиоцитов и в митохондриях лейкоцитов (r = 0,909; p < 0,0001). Заключение. Изменения энергетического обмена в лейкоцитах крови под влиянием цитопротекторов отражают аналогичные изменения, происходящие в клетках сердца.

1. 2020 Clinical practice guidelines for stable coronary artery disease. Russian Journal of Cardiology. 2020; 25(11): 4076. (In Russ.). doi: 10.15829/1560-4071-2020-4076

2. 2020 Clinical practice guidelines for chronic heart failure. Russian Journal of Cardiology. 2020; 25(11): 4083. (In Russ.). doi: 10.15829/1560-4071-2020-4083

3. Umehara T, Oka H, Nakahara A, Matsuno H, Murakami H. Differential leukocyte count is associated with clinical phenotype in Parkinson’s disease. J Neurol Sci. 2020; 409: 116638. doi: 10.1016/j.jns.2019.116638

4. Vinodh Rajkumar R. Exercise Performance and Immune Competence [EPIC: Background of natural immunity, immune diversity and immuno-iatrogenesis. Int J Physiother Res. 2022; 10(3): 4250-4268. doi: 10.16965/ijpr.2022.124

5. Schirrmacher V. Mitochondria at work: New insights into regulation and dysregulation of cellular energy supply and metabolism. Biomedicines. 2020; 8(11): 526. doi: 10.3390/biomedicines8110526

6. Zuurbier CJ, Bertrand L, Beauloye CR, Andreadou I, Ruiz‐Meana M, Jespersen NR, et al. Cardiac metabolism as a driver and therapeutic target of myocardial infarction. J Cell Mol Med. 2020; 24(11): 5937-5954. doi: 10.1111/jcmm.15180

7. Dard L, Blanchard W, Huber C, Lacombe D, Rossignol R. Mitochondrial functions and rare diseases. Mol Aspects Med. 2020; 71: 100842. doi: 10.1016/j.mam.2019.100842

8. Sukhorukov VS. Individual peculiarities of tissue energy metabolism and their role in the development of childhood diseases. Russian Bulletin of Perinatology and Pediatrics. 2011; 56(2): 4-11. (In Russ.)

9. Huang Z, Xie N, Illes P, Di Virgilio F, Ulrich H, Semyanov A, et al. From purines to purinergic signalling: Molecular functions and human diseases. Signal Transduct Target Ther. 2021; 6(1): 162. doi: 10.1038/s41392-021-00553-z

10. Romanov BK. Lysosome enzyme activity as a new diagnostic and prognostic criterium for the evaluation of cardiomyocyte damage rate. I.P. Pavlov Russian Medical Biological Herald. 2004; 1-2: 155-163. (In Russ.).

11. Dambrova M, Zuurbier CJ, Borutaite V, Liepinsh E, Makrecka-Kuka M. Energy substrate metabolism and mitochondrial oxidative stress in cardiac ischemia/reperfusion injury. Free Radic Biol Med. 2021; 165: 24-37. doi: 10.1016/j.freeradbiomed. 2021.01.036

12. Vasyuk YuA, Kulikov KG, Kudryakov ON, Krikunova OV, Sadulaeva IA. Secondary mitochondrial dysfunction in acute coronary syndrome. Rational Pharmacotherapy in Cardiology. 2007; 3(1): 41-47. (In Russ.). doi: 10.20996/1819-6446-2007-3-1-41-47

13. Vuononvirta J, Marelli-Berg FM, Poobalasingam T. Metabolic regulation of T lymphocyte motility and migration. Mol Aspects Med. 2021; 77: 100888. doi: 10.1016/j.mam.2020.100888

14. Hortová‐Kohoutková M, Lázničková P, Frič J. How immune‐cell fate and function are determined by metabolic pathway choice: The bioenergetics underlying the immune response. Bioessays. 2021; 43(2): 2000067. doi: 10.1002/bies.202000067

15. Koterov AN, Ushenkova LN, Zubenkova ES, Vaynson AA, Biryukov AP. Age relationships between major laboratory animals (mice, rats, hamsters and dogs) and humans: Relevance to age-related radiosensitivity and analysis of published data. Medical Radiology and Radiation Safety. 2018; 63(1): 5-27. (In Russ.). doi: 10.12737/article_5a82e4a3908213.56647014

16. Rogozhina AA, Averkova AO, Zubova YeA, Minushkina LO, Brazhnik VA, Ivanova ON, et al. Incidence of familial hypercholesterolemia in patients with early manifestations of coronary artery disease: Data from a Russian multicenter study and metaanalysis. Russian Journal of Cardiology. 2023; 28(10): 5587. (In Russ.). doi: 10.15829/1560-4071-2023-5587

17. Putilina FYe. Method for determining citrate synthase activity. In: Methods of biochemical research (lipid and energy metabolism). Ed. by M.I. Prokhorova. Leningrad: Leningrad University Publ., 1982: 179-181. (In Russ.).

18. Yeshchenko ND. Method for determining pyruvate dehydrogenase activity. In: Methods of biochemical research (lipid and energy metabolism). Ed. by M.I. Prokhorova. Leningrad: Leningrad University Publ., 1982: 192-195. (In Russ.).

19. Prochownik EV, Wang H. The metabolic fates of pyruvate in normal and neoplastic cells. Cells. 2021; 10(4): 762. doi: 10.3390/cells10040762

20. Maurer J, Hoene M, Weigert C. Signals from the circle: Tricarboxylic acid cycle intermediates as myometabokines. Metabolites. 2021; 11(8): 474. doi: 10.3390/metabo11080474

21. Roosterman D, Cottrell GS. Rethinking the citric acid cycle: Connecting pyruvate carboxylase and citrate synthase to the flow of energy and material. Int J Mol Sci. 2021; 22(2): 604. doi: 10.3390/ijms22020604

22. Guo Y, Pu WT. Cardiomyocyte maturation: New phase in development. Circ Res. 2020; 126(8): 1086-1106. doi: 10.1161/CIRCRESAHA.119.315862

23. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000; 86(5): 580-588. doi: 10.1161/01.res.86.5.580

24. Bobescu E, Marceanu LG, Dima L, Balan A, Strempel CG, Covaciu A. Trimetazidine therapy in coronary artery disease: The impact on oxidative stress, inflammation, endothelial dysfunction, and long-term prognosis. Am J Ther. 2021; 28(5): e540-e547. doi: 10.1097/MJT.0000000000001430

25. Romashchenko OV. Personalized trimetazidine prescription as a cytoprotective agent in patients with coronary artery disease. Russian Journal of Cardiology. 2021; 26(6): 106-114. (In Russ.). doi: 10.15829/1560-4071-2021-4532

26. Larina VN. Multisystem effect of cytoprotection. Consilium Medicum. 2021; 23(1): 93-98. (In Russ.). doi: 10.26442/20751753.2021.1.200732

27. Berlato DG, de Bairros AV. Meldonium: Pharmacological, toxicological, and analytical aspects. Toxicology Research and Application. 2020; 4. doi: 10.1177/2397847320915143

28. Nedogoda SV. Meldonium as a supernosological drug. Consilium Medicum. 2020; 22(5): 57-61. (In Russ.). doi: 10.26442/20751753.2020.5.200208

29. Shivakumar A, Yogendra Kumar MS. Critical review on the analytical mechanistic steps in the evaluation of antioxidant activity. Crit Rev Anal Chem. 2018; 48(3): 214-236. doi: 10.1080/10408347.2017.1400423

30. Zhigacheva VI, Krikunova IN, Binyukov IV, Mil E, Rusina I, Goloshchapov A. Etoxidol as a broad spectrum adaptogen. Curr Mol Pharmacol. 2023; 16(1): 109-115. doi: 10.2174/1874467215666220308115514

31. Romaschenko O, Pokrovsky M, Nadezhdin S, Rumbesht V, Zhernakova N, Alferov P, et al. Personalized approaches to the use of the antioxidant ethoxidol in patients with coronary heart disease. Journal of Nanostructures. 2022; 12(2): 343-352. doi: 10.22052/JNS.2022.02.011

32. Novikov VE, Levchenkova OS, Ivantsova EN, Vorobieva VV. Mitochondrial dysfunctions and antihypoxants. Reviewers on Clinical Pharmacology and Drug Therapy. 2019; 17(4): 30-41. (In Russ.). doi: 10.7816/RCF17431-42

33. Romashchenko O.V. The influence of cytoflavin on the viability of blood leukocytes in patients with ischemic heart disease. Experimental and Clinical Pharmacology. 2021; 84(3): 17-21. (In Russ.). doi: 10.30906/0869-2092-2021-84-3-17-21